Huntington’s Disease Related Content

Dr. James E Goldman and Dr. Osama Al-Dalahmah from the Department of Pathology and Cell Biology at Columbia University, discuss the importance of brain banking from individuals with Huntington’s disease.

Dr James E. Goldman, Professor of Pathology and Cell Biology at Columbia University, describes gaining more insight into disease mechanisms by comparing mouse genetic models with the human disease when it comes to Huntington’s Disease.

Chief Executive of the Huntington’s Disease Association, Cath Stanley, maps out the charities ongoing work to support its community, despite the COVID-19 pandemic.

Doctors Osama Al Dalahmah and James E. Goldman discuss their work on single Nuclei RNA sequencing of Huntington’s disease brain tissues.

Cecilia Van Cauwenberghe from Frost & Sullivan’s TechCasting Group, describes the present concern and future therapeutic perspective on Huntington’s disease.

Prof Dr Regina Fluhrer, from the University of Augsburg, explains how intramembrane proteases have been implicated in the emergence of neurodegenerative diseases.

Dr Gerry Morrow shares his thoughts on the rare, progressive neurodegenerative illness, Huntington’s disease (HD).

Chief Executive of the Huntington’s Disease Association, Cath Stanley shares the latest updates on Huntington’s research from the 2018 conference.

Astri Arnesen, President of the European Huntington Association argues that building a partnership with patients is the best way forward to promote better and sustainable health services

The National Academy of Sciences (PNAS) has published new research which reveals that Huntington's Disease may take affect in people much earlier on in life than originally expected and that a new drug may be paramount in controlling the disease.

Naoko Tanese from New York University School of Medicine outlines their work around Huntington’s disease (HD) and new targets for therapeutic intervention

Leora Fox, Jennifer Simpson and George Yohrling from the Huntington’s Disease Society of America explore the sources of funding in the development of therapies for Huntington’s disease (HD).

Professor Tanese of the New York University School of Medicine discusses Huntington’s disease Mutation in the huntingtin gene causes Huntington’s disease, a heritable and fatal neurodegenerative disease. The production of mutant huntingtin (HTT) protein is thought to be responsible for alterations of normal processes that ultimately result in the death of neurons....

Sorcha McPhillips, Chief Executive of the Huntington’s disease (HD) Association for Northern Ireland, raises awareness of HD and discusses the impact of hope on the community in the face of new treatments

Svein Olaf Olsen and Maiken Arnesen from the European Huntington Association reveal their thoughts on a recent and significant breakthrough concerning Huntington’s Disease (HD) research The 11th December 2017 will probably go into history along with the discovery of the Huntington gene in 1993. On this date, IONIS Pharmaceuticals announced...

The defect that causes Huntington's disease has been corrected in patients for the first time with an experimental drug Experts believe that the new experimental drug, which is injected into spinal fluid, could be the biggest breakthrough in neurodegenerative diseases for 50 years. The unstoppable death of brain cells in Huntington's gradually causes...

Prof. Dr Axel Rominger from the Ludwig-Maximilian-University of Munich on how neurodegenerative diseases can be studied through PET imaging

Chief Executive of the Huntington’s disease Association, Cath Stanley explores the symptoms, causes, and the vital role of research within the field

New York University School of Medicine’s Naoko Tanese explores the pathogenic mechanisms and therapeutic strategies for Huntington’s disease

Jennifer Simpson of the Huntington’s disease Society of America highlights the disease and how there is still a long way to go before it can be truly understood